Trials / Recruiting
RecruitingNCT05600842
De-escalated Radiation for Human Papillomavirus-Positive Squamous Cell Carcinoma of the Oropharynx
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 111 (estimated)
- Sponsor
- University of California, Irvine · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a single-arm, observational registry study determining the effects of reduced radiation dose in select patients with human papillomavirus (HPV) positive oropharyngeal cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | Intensity-Modulated Radiation Therapy (IMRT) | IMRT will be given in 30 daily fractions at 2 Gy per fraction (60 Gy total) beginning Day 1; Six fractions will be delivered per week. High risk patients will receive induction chemotherapy with 2 cycles of carboplatin and paclitaxel. |
Timeline
- Start date
- 2022-11-03
- Primary completion
- 2026-11-01
- Completion
- 2026-11-01
- First posted
- 2022-11-01
- Last updated
- 2025-02-25
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT05600842. Inclusion in this directory is not an endorsement.